Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients

This is a study composed by 2 groups of 50 patients undergoing VATS for lung cancer. All subjets will receive intraoperative intercostal nerve block with a maximum dose of 2 mg/kg of bupivacaine with epinephrine 1:200.000 at the beginning and at the end of procedure.

The control group will receive a bolus dose of dexamethasone (0.1 mg/kg) and the placebo group saline solution. The study drug or placebo will be administered at the time of anesthetic induction (approximately 30 minutes before surgical incision). Patients will be evaluated daily with the quality of recovery questionary, visual analogue pain and portable spirometry. And, the patients will have pulmonary lung function assessed by portable spirometry.

Inclusion criteria

• resectable stage I and II lung cancer patients submitted to VATS
• american society of anesthesiology Classification (ASA) I or II

Exclusion criteria

• chronic pain;
• chronic analgesic consumption;
• severe renal or liver disease;
• endocrine or mental diseases;
• poorly controlled diabetes;
• allergy to bupivacaine;
• previous thoracotomy;
• systemic use of corticosteroids;
• morbid obesity;
• poor French comprehension precluding completion of the QoR-40 questionnaire;
• patient refusal.